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Respiratory syncytial virus (RSV) is the single most
important lower respiratory tract pathogen in infants and
toddlers [1]. Up to 70% of the annual birth cohort are
infected during the first year of life [2], and 1–2% are
hospitalized annually for RSV bronchiolitis or pneumonia
[3, 4]. Since RSV is highly contagious, hospital admission
entails infection control measures for prevention of
contact and droplet transmission. Thus, clinicians should
have available a rapid test that identifies RSV-infected
patients quickly and reliably in the emergency room. The
test result enables the implementation of adequate infec-
tion control precautions at the time the patient is
transferred to the floor and provides a rationale for the
cohorting of patients with acute respiratory tract disease.
In addition, inadequate use of antibiotics may be avoided.
Bedside RSV rapid antigen detection systems have been
available for several years. Their usefulness in clinical
practice has been limited by relatively poor sensitivity.
Recently, two new test systems have become available
commercially. The purpose of the present study was to
compare these new assays with antigen detection using a
direct fluorescence assay (DFA).
During the 2002/2003 RSV peak season, nasopharyn-
geal secretions (NPS) from 30 children (median age,
5.4 months; range, 0.5–64 months) referred consecutively
to the emergency department of the University of Bern
Children’s Hospital for suspected RSV infection were
evaluated. NPS specimens were sampled transnasally
using a Vygon infant mucus aspirator (Vygon, Ecouen,
France), were brought to a total volume of 2.0 ml using
sterile normal saline, and were kept at 4C for a
maximum of 24 h before processing. Sample surplus
was stored at 80C. In addition to DFA (Light
Diagnostics Respiratory Panel DFA, Chemicon Interna-
tional, USA), which is currently the standard diagnostic
procedure used at this institution, aliquots of NPS were
tested using (i) the RSV OIA assay (OIA) (Thermo
BioStar, USA); (ii) the NOW RSV Test (Binax, USA);
(iii) RSV culture using shell vial technology; and, in
selected cases, (iv) reverse transcriptase polymerase chain
reaction (PCR) (Hexaplex; Prodesse, USA). All tests were
carried out according to the manufacturer’s instructions.
OIA and NOW were performed in the emergency
department by one of the authors (C.W.). DFA, culture
and PCR were performed by professional diagnostic
microbiology personnel. Detection of RSV by culture was
considered unequivocal proof of infection. Culture-neg-
ative samples testing positive in one of the antigen
detection assays were re-tested using PCR as the arbiter.
Thus, the gold standard consisted of a combination of
culture and PCR.
RSV was detected in 22 of 30 samples. Culture was
positive in 20 cases, PCR detected RSV RNA in two
additional cases. Overall, antigen test(s) yielded a positive
result in six culture-negative samples. PCR was positive
in two of these specimens. Table 1 summarizes the
performance of the two bedside RSV detection kits, OIA
and NOW, in comparison with DFA.
In this small population of young children with acute
respiratory tract illness and a high pre-test probability of
RSV infection, the three antigen detection kits performed
similarly (Table 1) and the results were comparable to
studies evaluating other rapid antigen detection systems
[5, 6, 7, 8]. These test performances are unlikely to be
applicable to inter-epidemic periods with low or absent
RSV activity and to older individuals in whom viral titers
in nasopharyngeal secretions are expected to be lower.
While DFA requires specific equipment (i.e., fluorescence
microscope) and trained personnel for reading the test
results, the test procedures for both OIA and NOW are
designed for bedside testing by non-laboratory personnel.
Both tests require approximately 15 min for completion.
The NOW test procedure is a single manual step, which
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consists of the administration of 100 ml of NPS to the test
strip using a calibrated pipet, and allows the test
performer to walk away during the incubation period.
The test surface is easy to read. In contrast, the OIA test
procedure is complex, involves the use of three different
reagents and a wash solution, and entails three incubation
steps. The OIA test is thus error-prone and clearly less
suitable for bedside RSV testing by non-laboratory
medical personnel. In addition, reading of the test surface
requires some experience. Both kits share a relatively low
negative predictive value. Until data from larger study
populations are available, backup testing using DFA,
culture or PCR is mandatory to rule out infection reliably
if clinical suspicion of RSV infection persists in a patient
tested negative. In summary, these two new tests offer
performance characteristics that are comparable to DFA
and other rapid antigen detection systems. Logistic and
quality control considerations clearly favor the NOW test
for bedside use in the pediatric emergency department.
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Table 1 Diagnostic performance of three respiratory syncytial virus (RSV) antigen detection assays
Method Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
RSV OIAa 87.5 75.0 90.5 66.7
RSV NOWb 86.4 100.0 100.0 72.7
RSV DFAc 95.5 100.0 100.0 88.9
a Respiratory Syncytial Virus Optical ImmunoAssay (Thermo BioStar, USA)
b Respiratory Syncytial Virus NOW RSV Test Kit (Binax, USA)
c Respiratory Syncytial Virus Direct Fluorescence Assay (Light Diagnostics Respiratory Panel DFA, Chemicon International, USA)
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